AUTHORS
Dan Feng, MD, Xianjing Zhang2, Rongli Zhang3, Jialin Wei4, Erlie Jiang, MD5
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
ABSTRACT
Background:
CEBPA mutations are recognized as favorable-risk molecular markers in acute myeloid leukemia (AML). However, despite the biological continuum between myelodysplastic syndromes (MDS) and AML, distinct clonal architectures and evolutionary trajectories may confer different biological implications to the same genetic alterations. Although CEBPA mutations have been incorporated into the IPSS-M model for MDS risk stratification, their molecular characteristics, evolutionary patterns, and clinical significance in the setting of allo-HSCT remain poorly defined. This study aimed to characterize the molecular landscape of CEBPA-mutated MDS and investigate its implications in the transplant setting.
Methods:
We analyzed 3,509 patients with MDS diagnosed between January 2020 and December 2025 from the NICHE real-world cohort at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, including 721 patients who underwent allo-HSCT. CEBPA mutation status was determined based on pre-transplant next-generation sequencing (NGS). Propensity score matching was performed to establish comparable cohorts of CEBPA-mutated and CEBPA-wildtype patients, followed by comparison of molecular features, mutational architecture, clonal evolution patterns, and post-transplant outcomes.
Results:
A total of 90 patients with MDS/sAML undergoing allo-HSCT were included, comprising 30 CEBPA-mutated patients and 60 CEBPA-wildtype patients. After propensity score matching, baseline characteristics, including age, sex, MDS subtype, IPSS-M risk category, pre-transplant disease status, and transplant-related factors, were well balanced between groups.
Compared with CEBPA-wildtype patients, CEBPA-mutated patients demonstrated a distinct molecular landscape, characterized by a higher frequency of normal karyotype (76.7% vs. 50.0%, P=0.03) and significant enrichment of STAG2 mutations (43.3% vs. 6.7%, P<0.01). ASXL1 and TET2 mutations also showed a trend toward increased frequency among CEBPA-mutated cases, suggesting a potentially distinct cooperating genetic context associated with CEBPA alterations in MDS.
Analysis of CEBPA evolution across disease stages revealed progressive clonal expansion. In MDS-EB1, CEBPA mutations were predominantly detected as low-level subclonal events, with a median VAF of 1.7%. The median VAF increased to 28.8% in MDS-EB2 and 43.8% in secondary AML (sAML). Furthermore, CEBPA mutational architecture showed disease-stage-associated changes, with frameshift/truncating alterations predominating in MDS-EB2, whereas in-frame alterations, particularly involving the bZIP region, were observed more frequently during progression to sAML. Domain analysis identified alterations involving the TAD region (n=8) and bZIP region (n=10), while only a minority of patients harbored combined TAD and bZIP alterations. These findings suggest that CEBPA-mutated MDS may exhibit a mutational architecture distinct from the canonical CEBPA-mutated AML pattern, with potential evolutionary remodeling during disease progression.
Despite incorporation into IPSS-M, CEBPA mutations did not reproduce the favorable prognostic phenotype observed in CEBPA-mutated AML. No significant differences were observed between CEBPA-mutated and CEBPA-wildtype patients in 3-year OS (61.2% vs. 71.0%, P=0.52) or EFS (61.5% vs. 64.0%, P=0.70). Although CEBPA-mutated patients showed a numerically lower cumulative incidence of relapse (3-year CIR: 7.4% vs. 15.9%), this potential benefit was offset by increased non-relapse mortality (3-year NRM: 31.1% vs. 20.1%), resulting in no survival advantage.
Among CEBPA-mutated patients, active disease before transplantation and abnormal karyotypes were associated with inferior survival trends, with 3-year OS rates of 48.5% versus 73.9% and 38.1% versus 71.6%, respectively. These findings suggest that CEBPA mutation alone may not fully determine transplant outcomes, while disease burden and cooperating genetic alterations may further influence the clinical behavior of CEBPA-mutated MDS.
Conclusion:
CEBPA-mutated MDS does not simply recapitulate the favorable-risk CEBPA subtype observed in AML, but appears to represent a distinct molecular and evolutionary state. The clinical significance of CEBPA alterations is highly context-dependent, highlighting the need for disease-specific interpretation of CEBPA mutations in MDS rather than direct extrapolation from AML.
DISCLOSURES
Dan Feng, MD: No relevant conflicts of interest to declare.